Human reproduction最新文献

{"title":"A core outcome set for future male infertility research: development of an international consensus","authors":"Michael P Rimmer, Ruth A Howie, Richard A Anderson, Christopher L R Barratt, Kurt T Barnhart, Yusuf Beebeejaun, Ricardo Pimenta Bertolla, Pietro Bortoletto, Robert E Brannigan, Astrid E P Cantineau, Ettore Caroppo, Barbara L Collura, Kevin Coward, William Colin Duncan, Michael L Eisenberg, Steven A Gellatly, Christian De Geyter, Dimitrios G Goulis, Ralf R Henkel, Vu N A Ho, Alayman F Hussein, Carin Huyser, Jozef H Kadijk, Mohan S Kamath, Shadi Khashaba, Hajra Khattak, Yoshitomo Kobori, Julia Kopeika, Tansu Kucuk, Saturnino Luján, Thabo Christopher Matsaseng, Raj S Mathur, Kevin McEleny, Rod T Mitchell, Ben W Mol, Alfred M Murage, Ernest H Y Ng, Allan Pacey, Antti H Perheentupa, Stefan Du Plessis, Nathalie Rives, Ippokratis Sarris, Peter N Schlegel, Majid Shabbir, Maciej Śmiechowski, Venkatesh Subramanian, Sesh K Sunkara, Basil C Tarlarzis, Frank Tüttelmann, Andy Vail, Madelon van Wely, Mónica H Vazquez-Levin, Lan N Vuong, Alex Y Wang, Rui Wang, James M N Duffy, Cindy M Farquhar, Craig Niederberger","doi":"10.1093/humrep/deaf039","DOIUrl":"https://doi.org/10.1093/humrep/deaf039","url":null,"abstract":"STUDY QUESTION Can a core outcome set be developed through a global consensus to standardize outcome selection, collection, comparison, and reporting in future male infertility trials? SUMMARY ANSWER A minimum dataset, known as a ‘core outcome set’, has been developed for randomized controlled trials (RCTs) and systematic reviews evaluating potential interventions for male infertility. WHAT IS KNOWN ALREADY Numerous factors, including a failure to consider the perspectives of men with lived experiences of infertility or their partners when developing and conducting RCTs can limit their clinical utility. Selection of outcomes, variations in outcome definitions, and the selective reporting of outcomes based on statistical analysis make the results of infertility research challenging to interpret, compare, and implement. For male infertility, this is further compounded by there being potentially three participants, the male, their female partner, and any offspring born, all with outcomes to be reported. This has led to significant heterogeneity in trial design and reporting. While a core outcome set for general infertility trials has been developed, there is no such outcome set for male infertility trials. STUDY DESIGN, SIZE, DURATION A two-round Delphi survey (334 participants from 39 countries) and consensus development workshops (44 participants from 21 countries). PARTICIPANTS/MATERIALS, SETTING, METHODS Healthcare professionals, researchers, and men and women with infertility were brought together in a transparent process using formal consensus science methods. MAIN RESULTS AND THE ROLE OF CHANCE The core outcome set for male infertility trials has been developed by the inclusion of specific male-factor outcomes in addition to the general infertility core outcome set. These outcomes include assessment of semen using the World Health Organization recommendations for semen analysis; viable intrauterine pregnancy confirmed by ultrasound (accounting for singleton, twin, and higher multiple pregnancies); pregnancy loss (accounting for ectopic pregnancy, miscarriage, stillbirth, and termination of pregnancy); live birth; gestational age at delivery; birthweight; neonatal mortality; and major congenital anomaly. Although not a requirement as part of the core outcome set, other outcomes were identified as potentially useful in certain study settings. LIMITATIONS, REASONS FOR CAUTION We used consensus development methods in this work, which have inherent limitations, including the representativeness of the participant sample, Delphi survey attrition, and an arbitrary consensus threshold. WIDER IMPLICATIONS OF THE FINDINGS Embedding the core outcome set within RCTs and systematic reviews should ensure the comprehensive selection, collection, and reporting of core outcomes, which are inconsistently reported at present. Research funding bodies, the Standard Protocol Items: Recommendations for Interventional Trials (SPIRIT) statement, and over 80 specialty ","PeriodicalId":13003,"journal":{"name":"Human reproduction","volume":"2 1","pages":""},"PeriodicalIF":6.1,"publicationDate":"2025-04-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143836921","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"COVID-19 vaccination and pregnancy-induced hypertension risk in women undergoing assisted reproduction.","authors":"Shujuan Ma,Yixiang Zheng,Mingli Fang,Yiquan Xiong,Liang Hu,Yvonne Liu,Fei Gong,Bernhard K Krämer,Ge Lin,Berthold Hocher","doi":"10.1093/humrep/deaf055","DOIUrl":"https://doi.org/10.1093/humrep/deaf055","url":null,"abstract":"STUDY QUESTIONDoes COVID-19 vaccination affect the risk of pregnancy-induced hypertension (PIH) in women undergoing ARTs, and does this risk differ based on vaccine type (inactivated vs recombinant) and timing relative to embryo transfer?SUMMARY ANSWERWomen who received inactivated COVID-19 vaccines before undergoing ART had a significantly increased risk of developing PIH, particularly when vaccinated with two or more doses or when embryo transfer occurred within 1 month of vaccination.WHAT IS KNOWN ALREADYCOVID-19 vaccination during pregnancy reduces the risk of severe COVID-19 illness with no significant safety concerns for the mother or fetus. PIH is a common complication in ART pregnancies, particularly in older women and those with higher BMI, but the effects of different COVID-19 vaccine types on PIH risk in ART pregnancies remain unclear.STUDY DESIGN, SIZE, DURATIONA retrospective cohort study analyzing 3911 women undergoing ART after receiving COVID-19 vaccines. The study period spanned from 1 December 2020 to 30 September 2022.PARTICIPANTS/MATERIALS, SETTING, METHODSParticipants were categorized based on COVID-19 vaccination status, vaccine type (inactivated vs recombinant), and the timing of vaccination relative to embryo transfer. The primary outcome was the development of PIH. Multivariate robust Poisson regression was used to assess the association between vaccination and PIH, while subgroup analyses explored the risk across variables like age, BMI, and embryo transfer type.MAIN RESULTS AND THE ROLE OF CHANCEWomen vaccinated with an inactivated COVID-19 vaccine prior to embryo transfer had a significantly higher incidence of PIH compared to unvaccinated counterparts (relative risk [RR] = 1.45; 95% CI 1.10-1.92; P = 0.009). In contrast, recombinant vaccines did not show a significant association with increased PIH risk (RR = 1.19; 95% CI 0.69-2.05; P = 0.537). The risk was particularly pronounced among women receiving two or more doses of the inactivated vaccines and those who had embryo transfers within 1 month of vaccination. Subgroup analyses showed elevated PIH risk in women aged ≥30 years old, those with BMI ≥22 kg/m2, individuals with secondary infertility, and those undergoing cleavage-stage or fresh embryo transfers.LIMITATIONS, REASONS FOR CAUTIONThe study's retrospective design limits causal inference. The sample is from a single ethnic background, and familial hypertension history was not available, potentially introducing residual confounding.WIDER IMPLICATIONS OF THE FINDINGSThe study suggests that the type and timing of COVID-19 vaccination may influence PIH risk in ART pregnancies. These findings underscore the need for careful consideration of vaccination type and timing in ART protocols and highlight the importance of further prospective studies to validate these results before influencing clinical decision-making.STUDY FUNDING/COMPETING INTEREST(S)This work was supported by the Hunan High-Level Talent Aggregation Pr","PeriodicalId":13003,"journal":{"name":"Human reproduction","volume":"119 1","pages":""},"PeriodicalIF":6.1,"publicationDate":"2025-04-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143827097","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Parents facing polygenic embryo scores: the ‘best choice of a best life’ and psychological counselling","authors":"Marina Forte, Daniela Galliano, Anna Maria Della Vedova, Antonio Pellicer","doi":"10.1093/humrep/deaf056","DOIUrl":"https://doi.org/10.1093/humrep/deaf056","url":null,"abstract":"Advances in reproductive medicine and genetic technologies now offer prospective parents the option to test IVF embryos for genetic predispositions to complex diseases, such as coronary heart disease and psychiatric disorders, through polygenic embryo screening (PES). However, limited clinical data on its real-world use leaves parents facing complex decisions based on probabilistic risk scores, requiring them to weigh uncertain benefits against potential harms. While clinical, ethical, and societal concerns regarding PES have been extensively discussed, the psychological considerations have received less attention. This paper highlights the importance of decision aids as part of psychological interventions, which are crucial for helping parents navigate these choices and make informed decisions based on individual perceptions and experiences. Additionally, determining how and when to disclose genetic risk information to children presents significant challenges for families. Early disclosure may lead to anxiety, while withholding information could undermine trust later in life. Psychological counseling is therefore an essential component in supporting families through these sensitive decisions. While PES offers opportunities to reduce genetic risks, it also introduces significant challenges that require thoughtful consideration and comprehensive support for both parents and children.","PeriodicalId":13003,"journal":{"name":"Human reproduction","volume":"75 1","pages":""},"PeriodicalIF":6.1,"publicationDate":"2025-04-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143813527","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"'And Then There Were None'-the shrinkage of trials in the evidence ecosystem.","authors":"Rui Wang","doi":"10.1093/humrep/deaf064","DOIUrl":"https://doi.org/10.1093/humrep/deaf064","url":null,"abstract":"","PeriodicalId":13003,"journal":{"name":"Human reproduction","volume":"26 1","pages":""},"PeriodicalIF":6.1,"publicationDate":"2025-04-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143819295","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Empirical use of growth hormone in IVF makes no sense.","authors":"Norbert Gleicher","doi":"10.1093/humrep/deaf059","DOIUrl":"https://doi.org/10.1093/humrep/deaf059","url":null,"abstract":"","PeriodicalId":13003,"journal":{"name":"Human reproduction","volume":" ","pages":""},"PeriodicalIF":6.0,"publicationDate":"2025-04-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143811316","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Growth hormone is not an ovulation induction agent.","authors":"Ulun Ulug","doi":"10.1093/humrep/deaf060","DOIUrl":"https://doi.org/10.1093/humrep/deaf060","url":null,"abstract":"","PeriodicalId":13003,"journal":{"name":"Human reproduction","volume":" ","pages":""},"PeriodicalIF":6.0,"publicationDate":"2025-04-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143811318","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Reply. Challenging the status quo: the future of growth hormone in IVF treatment.","authors":"Isaac-Jacques Kadoch","doi":"10.1093/humrep/deaf061","DOIUrl":"https://doi.org/10.1093/humrep/deaf061","url":null,"abstract":"","PeriodicalId":13003,"journal":{"name":"Human reproduction","volume":" ","pages":""},"PeriodicalIF":6.0,"publicationDate":"2025-04-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143811320","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Randomized controlled trial to evaluate the impact of follicle priming on IVM outcomes in women with polycystic ovaries: CFA versus FSH-B.","authors":"Michel De Vos, Linde Mostinckx, Panagiotis Drakopoulos, Ellen Anckaert, Johan Smitz, Shari Mackens, Christophe Blockeel, Ingrid Segers","doi":"10.1093/humrep/deaf053","DOIUrl":"https://doi.org/10.1093/humrep/deaf053","url":null,"abstract":"<p><strong>Study question: </strong>Do corifollitropin alfa (CFA) and follitropin beta (FSH-B) have different effects on oocyte yield and live birth rates (LBRs) after IVM in women with polycystic ovaries?</p><p><strong>Summary answer: </strong>In patients who underwent IVM, one injection of CFA resulted in lower oocyte retrieval rates, but similar cumulative LBRs compared to three injections of FSH-B.</p><p><strong>What is known already: </strong>IVM involves the maturation of cumulus-oocyte complexes (COCs) from antral follicles and has been offered to women with polycystic ovaries as an alternative for conventional ovarian stimulation (OS). A short course of exogenous FSH is typically administered in IVM cycles to enhance meiotic and developmental competence of immature oocytes in vivo. Previous studies have shown that the number of COCs is associated with pregnancy rates after IVM. Because one injection of CFA yields more oocytes compared to daily FSH-B injections in conventional OS protocols, CFA has the potential to combine patient-friendliness and maximum COC yield in IVM cycles.</p><p><strong>Study design, size, duration: </strong>We conducted a randomized controlled superiority trial from November 2017 to December 2022. The primary endpoint was the number of COCs at oocyte retrieval. We randomized 145 patients to either one injection of 100 μg CFA or three daily injections of 150 IU FSH-B. Laboratory and safety parameters, and pregnancy outcomes after frozen embryo transfer (FET) were analysed on an intention-to-treat (ITT) basis. All cycles were scheduled using oral contraceptive pre-treatment.</p><p><strong>Participants/materials, settings, methods: </strong>Eligible patients were <37 years, had ≥24 antral follicles and an anti-Müllerian hormone ≥3.25 ng/ml, and BMI 18-30 kg/m2. We analysed serum oestradiol, progesterone, LH, and FSH on stimulation days 1 and 3, at oocyte retrieval, and at 6 days after oocyte retrieval. No ovulation trigger was given. Oocyte retrieval was performed 5 days after the start of OS. COCs were incubated in monophasic IVM media for 30 h. After ICSI, an elective freeze-only strategy was performed. Data were analysed using STATA 13.0.</p><p><strong>Main results and the role of chance: </strong>After randomization, 70 patients underwent oocyte retrieval after FSH-B and 72 had oocyte retrieval after CFA. According to the ITT analysis, hormone levels at oocyte retrieval were significantly different between FSH-B-treated and CFA-treated patients (FSH 6.4 ± 3.1 IU/l vs 22.6 ± 9.8 IU/l, P < 0.001; LH 3.1 ± 2.7 IU/l vs 1.6 ± 1.6 IU/l, P = 0.002; E2 100.8 ± 144.9 ng/l vs 536.2 ± 519.0 ng/l, P < 001; Prog 0.17 ± 0.16 μg/l vs 0.26 ± 0.21 μg/l, P < 0.001, respectively). On average, 37.7 ± 24.8 (FSH-B) versus 45.9 ± 31.5 (CFA) follicles, all <10 mm, were punctured during oocyte retrieval (P = 0.06). More COCs per follicle were retrieved after FSH-B (59.8 ± 37.2% vs 46.1 ± 27.9%, P = 0.02), resulting in more COCs after FSH-","PeriodicalId":13003,"journal":{"name":"Human reproduction","volume":" ","pages":""},"PeriodicalIF":6.0,"publicationDate":"2025-04-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143803269","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Adoptive transfer of regulatory T cells inhibits the progression of endometriosis-like lesions in regulatory T-cell-depleted mice","authors":"Eiko Maeda, Hiroyuki Okimura, Yukiko Tanaka, Maya Fujii, Yosuke Tarumi, Hisashi Kataoka, Akemi Koshiba, Masahide Hamaguchi, Michiaki Fukui, Taisuke Mori, Jo Kitawaki","doi":"10.1093/humrep/deaf054","DOIUrl":"https://doi.org/10.1093/humrep/deaf054","url":null,"abstract":"STUDY QUESTION Does the restoration of regulatory T cells (Tregs) suppress the progression of endometriosis? SUMMARY ANSWER Adoptive transfer of Tregs suppresses the progression of endometriosis and reduces the levels of helper T (Th)-cell-related and proinflammatory cytokines in mice. WHAT IS KNOWN ALREADY Endometriosis is a chronic inflammatory gynecological disease, which involves multiple immune components. Activated Treg counts decrease in the endometrioma and endometrium of patients with endometriosis, and depletion of Tregs exacerbates endometriosis in mice. STUDY DESIGN, SIZE, DURATION We evaluated the effects of adoptive transfer of Tregs on the progression of endometriosis in mice. We used Foxp3tm3Ayr/J (Foxp3DTR) mice with temporarily ablated Tregs by injecting diphtheria toxin to develop an endometriosis model, which was generated by ovariectomy, estradiol administration and transplantation of uterine fragments from donor mice. Foxp3DTR mice were randomly divided into Treg adoptive transfer (n = 12) and control (n = 11) groups. Tregs were isolated from lymph nodes and spleens of wild-type (WT) mice and were adoptively transferred into mice that were temporarily Treg-depleted. Control mice were injected with vehicle. Treg adoptive transfer was performed on the day of uterine implantation, and a second adoptive transfer was performed after 14 days. Mice were euthanized 28 days after uterine implantation, and blood, peritoneal fluid, spleen, and endometriosis-like lesion samples were collected. PARTICIPANTS/MATERIALS, SETTING, METHODS Foxp3DTR mice were intravenously injected with Tregs isolated from WT mice. The number, total weight, and total volume of the endometriosis-like lesions were evaluated on Day 28 following implantation of uterine fragments. The proportion of Tregs in endometriosis-like lesions, ascites, and peripheral blood was analyzed by flow cytometry. Inflammation in lesions and serum was examined using real-time PCR and ELISA. MAIN RESULTS AND THE ROLE OF CHANCE Injection of Tregs increased their total count and decreased the number (P < 0.0001), weight (P = 0.0021), and volume (P = 0.0010) of endometriosis-like lesions in Foxp3DTR Treg-depleted mice. Furthermore, injection of Tregs decreased the mRNA expression of Th 1-, 2-, and 17-related cytokines, including interferon gamma (P = 0.0101), interleukin (IL)-4 (P = 0.0051), and IL-17 (P = 0.0177), as well as the levels of the proinflammatory cytokine IL-6 (P = 0.0002), in endometriosis-like lesions of Foxp3DTR Treg-depleted mice. LARGE SCALE DATA N/A. LIMITATIONS, REASONS FOR CAUTION Treg-related immune mechanisms in mice may not precisely reflect those in humans. WIDER IMPLICATIONS OF THE FINDINGS Restoration of Tregs may be a useful therapeutic strategy for inhibiting the progression of endometriosis in cases where the decrease in the Treg population is an exacerbating factor. STUDY FUNDING/COMPETING INTEREST(S) This study was partially supported by the Grants-","PeriodicalId":13003,"journal":{"name":"Human reproduction","volume":"15 1","pages":""},"PeriodicalIF":6.1,"publicationDate":"2025-04-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143775523","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Correction to: Endometriosis and risk of depression among oral contraceptive users: a pooled analysis of cohort studies from 13 countries.","authors":"","doi":"10.1093/humrep/deaf065","DOIUrl":"https://doi.org/10.1093/humrep/deaf065","url":null,"abstract":"","PeriodicalId":13003,"journal":{"name":"Human reproduction","volume":" ","pages":""},"PeriodicalIF":6.0,"publicationDate":"2025-04-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143779846","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}